Clinical Trial Detail

NCT ID NCT02317991
Title Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer
Recruitment Active, not recruiting
Gender
Phase Phase II
Variant Requirements No
Sponsors SCRI Development Innovations, LLC
Indications

gastric adenocarcinoma

esophagus adenocarcinoma

gastroesophageal junction adenocarcinoma

Therapies

Nab-paclitaxel + Ramucirumab

Age Groups:

No variant requirements are available.